Maasziekenhuis Pantein B.V.
- Address
- Dokter Kopstraat 1, 5835 DV Beugen, The Netherlands
Maasziekenhuis Pantein B.V.
Maasziekenhuis Pantein B.V. is a clinical research center with demonstrated expertise in oncology and cardiovascular disease research. The center participates in pivotal trials investigating novel therapeutic strategies and precision medicine approaches across multiple disease areas.
- Advanced breast cancer treatment optimization with endocrine therapy and CDK 4/6 inhibition
- Genotype-guided antithrombotic therapy for peripheral arterial disease management
- Multiple myeloma treatment strategies with novel immunotherapy combinations
The research portfolio reflects a commitment to evaluating innovative treatment sequencing strategies in hormone receptor positive breast cancer, precision medicine applications in peripheral arterial disease to reduce cardiovascular and limb-related complications, and exploring treatment-free intervals in newly diagnosed multiple myeloma using daratumumab-based regimens. This diverse oncology and cardiovascular focus positions the center at the forefront of personalized medicine and quality-of-life optimization in cancer care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Maasziekenhuis Pantein B.V.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of CDK4/6 Inhibitors Abemaciclib, Palbociclib, and Ribociclib in HR+/HER2- Metastatic Breast Cancer: A Randomized Clinical Trial | BOOG Study Center B.V. | Phase III | Not Recruiting | Nov 2017 | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abemaciclib | 1 | Unknown | 2017-11-21 | 2017-11-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.